Sanction: The Paris Court of Appeal reduces the penalty imposed on a pharmaceutical company by €4 million, but essentially confirms the French Competition Authority’s analysis on the delay in generic entry (Janssen-Cilag, Johnson & Johnson)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. On 11 July 2019, the Paris Court of Appeal handed down a ruling in the case of the delay in the entry of generics of Durogesic. It will be recalled that by a decision rendered on December 20, 2017In its decision of 25 March 2008, the Competition Authority sanctioned the laboratory Janssen-Cilag, as the perpetrator, and its parent company Johnson & Johnson - imputability obliges - to the tune of EUR 25 million, for having carried out, from 25 March 2008 to mid-August 2009, that is to say, for 16 months, two practices constituting a complex and continuous infringement aimed at preventing, then to limit the penetration of generic competitors of the